Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

The company's expertise in gene editing could lead to more breakthroughs.

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive license agreement with KU Leuven covering CRISPR/Cas9 activities at the Leuven ...

OpenAI used nearly 2,000 GPT-Rosalind agents to analyze an 8-million-cell mouse brain CRISPR atlas in 32 minutes, flagging a ...

Late last month, Anthropic claimed it had discovered a curious stretch of DNA in a virus called a bacteriophage that repeats ...

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear. But the work marks a major advancement because the A.I. made this discovery ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

A 2026 review describes CRISPR-Cas as a promising strategy for addressing drug-resistant Pseudomonas aeruginosa infections ...

CRISPR released its second-quarter financials and business update early in the month, on Aug. 3, to be exact. It quoted CEO Samarth Kulkarni as saying that this "reflected strong execution across ...